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Syndecan-1 (CD138), a member of the transmembrane heparan sulfate proteoglycan family, acts as an extracellular matrix receptor 1, 2 and is involved in many cellular functions, including cell-cell adhesion and cell-matrix adhesion. Expression of syndecan-1 typically is observed on the surface of mature epithelial cells; however, stromal expression also might be seen in developing tissues. [3] [4] [5] [6] Within the hematopoietic system, syndecan-1 expression is thought to be restricted to normal and malignant plasma cells. [7] [8] [9] Based on messenger RNA studies, high levels of syndecan-1 have been detected only for cells at precursor B-cell and plasma cell stages of Bcell differentiation. In vitro evidence supports a role for CD138 in plasma cell adherence to bone marrow stromal matrix via an interaction with type I collagen. 10 Monoclonal antibodies of the CD138 cluster (clones B-B4, Mi15) that recognize human syndecan-1 have been developed and seem to be plasma cell-specific among hematopoietic elements. 7, 8 Immunohistochemical studies of bone marrow biopsy specimens using monoclonal antibodies for the detection of CD138 have shown that these reagents are reliable for the identification and quantitation of normal and neoplastic plasma cells and, thus, are useful for the evaluation and classification of hematologic malignant neoplasms. 8, 9, 11, 12 In addition to plasma cells, CD138 reactivity also has been described for the plasmacytoid tumor cells of herpesvirusassociated effusion lymphomas 13 and has been reported with variable frequency in immunoblastic diffuse large Bcell lymphoma (DLBCL). 8 However, few studies have included large numbers of hematopoietic malignant neoplasms, and limited data are available regarding the spectrum of syndecan-1/CD138 reactivity in human nonhematopoietic tumors.
Syndecan-1 expression is present in mature epithelial cells, particularly squamous and transitional types, but in murine studies reportedly is absent in endothelial cells and normal adult mesenchymal cells. 14 A correlation between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck has been reported, with syndecan-1-positive tumors exhibiting higher overall and disease-free survival. 15 In studies of breast carcinomas, weak CD138 expression in malignant ductal cells associated with extensive stromal staining has been described. 16 CD138 positivity also has been reported in a variety of soft tissue tumors. 17 A correlation between CD138 expression and cell differentiation in mesothelioma has been noted. 18 Given this staining profile, CD138 reactivity for malignant tumors of unknown origin might create difficulty in the assessment of hematopoietic tissue, particularly because the cytologic features of some epithelial neoplasms might suggest plasmacytic differentiation.
The present study further defines the spectrum of CD138 immunoreactivity in a broad range of hematologic and nonhematologic neoplasms in routinely processed tissue sections and evaluates the potential role of CD138 as a diagnostic discriminant.
Materials and Methods
A total of 238 cases were retrieved from the surgical pathology files of the Brigham and Women's Hospital, Boston, MA. Diagnoses were established on the basis of light microscopic and immunophenotypic studies and/or clinical studies. Specimens included 91 bone marrow biopsy specimens, all fixed in Zenker-acetic acid solution, 14 nonneoplastic lymph nodes, 77 hematopoietic neoplasms (49 nodal, 28 extranodal tissue samples), and 56 nonhematopoietic neoplasms from various sites. Most of the latter 147 tissue samples were fixed in formalin (n = 110); 37 specimens were fixed in B-5 solution (all representing hematopoietic disorders). Tissue samples were processed routinely and embedded in paraffin. Bone marrow biopsy specimens ❚Table 1❚ included 79 cases of hematologic neoplasms encompassing a broad spectrum of non-Hodgkin lymphoma (NHL), lymphocytic and myelogenous leukemias, and plasma cell dyscrasias; 9 biopsy specimens with metastatic carcinoma (6 breast, 1 prostate, 1 esophageal, and 1 neuroendocrine carcinoma), and 3 nonneoplastic bone marrow biopsy specimens (erythroid hyperplasia, myeloid hyperplasia, and a remission marrow specimen from a patient previously treated for acute myelogenous leukemia).
The 77 cases of hematologic neoplasms (49 lymph nodes and 28 biopsy specimens of extranodal tissues from sites including spleen, ovary, lung, thyroid, salivary gland, soft tissue, and skin) included a wide variety of NHLs, ie, DLBCL, marginal zone lymphoma (nodal, extranodal, and splenic), follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma, EpsteinBarr virus-positive posttransplant lymphoproliferative disorder, mediastinal large B-cell lymphoma, and Langerhans cell histiocytosis ❚Table 2❚. Fourteen lymph nodes of nonneoplastic proliferations also were evaluated and included reactive lymphadenopathy (n = 5), HIV-related lymphadenopathy (n = 2), and 1 case each of cytomegalovirus lymphadenitis, dermatopathic lymphadenopathy, granulomatous lymphadenitis, infectious mononucleosis, RosaiDorfman disease, Castleman disease, and Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis). Studies also were performed on tissue microarrays (provided by Andrew Weng, MD, PhD, Brigham and Women's Hospital) of formalin-fixed, paraffin-embedded sections of additional DLBCL (44 cases), grade 1/3 follicular lymphoma (14 cases), and nodular sclerosis Hodgkin lymphoma (2 cases).
Fifty-six biopsy specimens of nonhematologic neoplasms ❚Table 3❚ encompassed a variety of epithelial tumors, both primary and metastatic, including hepatocellular carcinoma, colonic adenocarcinoma, renal cell carcinoma, breast carcinoma, gastric carcinoma, small and non-small cell lung carcinoma, transitional cell carcinomas, medullary and papillary carcinomas of the thyroid, myoepithelioma of the salivary gland, and thymoma. Other neoplasms examined included melanoma, mesothelioma, seminoma, pheochromocytoma, leiomyosarcoma, schwannoma, synovial sarcoma, and gastrointestinal stromal tumor. Nonneoplastic tissue samples also were evaluated, including tonsil, prostate, nerve, myometrium, pancreas, skin, and thymus.
Immunohistochemical studies were performed on paraffin sections of Zenker-, B-5-, or formalin-fixed tissue samples. Negative control studies were performed by substituting mouse isotype-specific (IgG1) immunoglobulin of the appropriate protein concentration for the primary antibody.
Sections were deparaffinized, and the mercury salts were removed from Zenker-or B-5-fixed tissue. Preliminary studies demonstrated that antigen retrieval was not required for Zenker-fixed sections. For B-5-or formalin-fixed tissue sections, immunoreactivity was improved following heatinduced epitope retrieval in a steamer (model HS80, Black & Decker, Shelton, CT) using a 0.001-mol/L EDTA solution, pH 8.0, for 30 minutes. Slides then were allowed to cool at room temperature for 20 minutes, washed with water, and placed in methanolic-peroxide (5:1 vol/vol, methanol/3% hydrogen peroxide) for 20 minutes. Slides were washed and then placed in a 0.05-mol/L concentration of tris(hydroxymethyl)aminomethane (Tris) buffer, pH 7.6, supplemented with 3% porcine serum. Sections were incubated for 1 hour with monoclonal antibody to CD138/syndecan-1 (clone B-B4, 1:80 dilution for Zenker-fixed tissue samples, 1:40 dilution for B-5-or formalin-fixed tissue samples; Serotec, Raleigh, NC), washed with Tris-saline, followed by incubation with peroxidase-labeled polymer conjugated to goat antimouse immunoglobulin antibody (ImmunoVision, Daly City, CA, or EnVision+, DAKO, Carpinteria, CA) for 30 minutes, and then washed with Tris-saline.
Antibody localization was effected by using a peroxidase reaction with 3,3'-diaminobenzidine tetrahydrochloride (DAB+, DAKO) as the chromogen. The staining reaction was intensified by using DAB enhancing solution (Zymed Laboratories, South San Francisco, CA). Slides were washed with water, counterstained with hematoxylin, dehydrated, and mounted with Poly Mount (Poly Scientific, Bay Shore, NY).
In all cases, staining intensity and the extent of staining, either focal or diffuse (most cells reactive), was determined, as was the staining pattern (eg, membranous, cytoplasmic). Stromal reactivity also was assessed. Plasma cells that were present in almost all cases served as positive internal controls. Cases of multiple myeloma also represented positive controls.
Results

Bone Marrow Biopsy Specimens
Of the 79 bone marrow biopsy specimens involved by a wide spectrum of hematologic disorders, in all cases, CD138 reactivity was observed for nonneoplastic plasma cells, which occurred in a scattered and/or perivascular distribution, and for neoplastic plasma cells in all cases of multiple myeloma and the plasmacytic component of lymphoplasmacytic lymphomas (Table 1 ). All 43 biopsy specimens involved by multiple myeloma showed strong CD138 reactivity with a staining pattern characterized by prominent membrane accentuation ❚Image 1❚. All plasma cells in an individual case seemed to be positive and included sheets, clusters, aggregates, and single cells. In 7 cases, weak stromal reactivity also was noted. The 4 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia showed strong membrane reactivity that was limited to the plasma cell component of the neoplastic infiltrate ❚Image 2❚. All other bone marrow elements (hematopoietic, mast cells, bone trabeculae, and vascular elements) were CD138-.
Neoplastic cells in 5 of 9 bone marrow biopsy specimens containing metastatic carcinoma were CD138+ (breast Table 1 ). Reactivity was noted for all or nearly all neoplastic cells, was moderate to strong in intensity, and was predominantly membranous ❚Image 3A❚. All cases of metastatic breast carcinoma also exhibited stromal reactivity, irrespective of whether the tumor cells were positive ❚Image 3B❚. Strong stromal staining in the absence of tumor cell positivity also was present in 2 cases of metastatic esophageal and neuroendocrine carcinoma. In some cases involved by metastatic breast carcinoma, the morphologic features of the neoplastic cells (routine sections) potentially could be confused with a plasmacytic infiltrate (Image 3A).
Lymph Nodes and Extranodal Tissues: Hematopoietic Disorders
Evaluation of a wide variety of NHLs (Table 2 ) revealed CD138 reactivity in only 6 of 57 cases, 2 of which represented DLBCL of the immunoblastic subtype that exhibited plasmacytoid features. Immunoreactivity in both cases was strong, diffuse, and membranous ❚Image 4❚. CD138 
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❚Image 3❚ Metastatic carcinoma of breast, bone marrow biopsy specimen, Zenker fixation. A, Tumor cells in this metastatic lobular carcinoma exhibit plasmacytoid morphologic features and reveal strong membrane reactivity for CD138. A study for keratin proteins (AE1/AE3) confirmed their epithelial derivation (immunoperoxidase study, hematoxylin counterstain, ×600). B, In this metastatic ductal carcinoma, neoplastic cells are CD138-; however, strong stromal reactivity is present. A few CD138+ plasma cells also are present (immunoperoxidase study, hematoxylin counterstain, ×400).
sclerosis, 7; mixed cellularity, 1 Table 2) . With inclusion of these cases, CD138 reactivity was evaluated in a total of 216 hematologic disorders (this number excludes studies on nonneoplastic tissues).
Strong CD138 reactivity was observed for the nonneoplastic epithelial components of extranodal tissues, eg, salivary gland. Skin biopsies revealed uniform positivity of the epithelial cells in a membranous pattern, providing a positive internal control. In the reactive nodes, strong CD138 reactivity was observed for benign plasma cells. Other nodal elements were nonreactive. A delicate pattern of stromal staining was noted in cases of Castleman disease and RosaiDorfman disease.
Nonhematopoietic Disorders
We studied 56 cases of nonhematopoietic neoplasms (Table 3) . Almost all epithelial neoplasms (32/35 cases) exhibited immunoreactivity for CD138, including breast carcinoma, gastric carcinoma, small cell and non-small cell lung carcinoma, hepatocellular carcinoma, colonic adenocarcinoma, renal cell carcinoma, transitional cell carcinoma, medullary carcinoma of the thyroid, papillary carcinoma of the thyroid, and thymoma ❚Image 5❚, ❚Image 6❚, ❚Image 7❚, and ❚Image 8❚. Primary (20 cases) and metastatic (15 cases) tumors were evaluated, and no difference in reactivity was observed between the 2 groups. Of note, 1 case of salivary ❚Image 4❚ Diffuse large B-cell lymphoma, immunoblastic with plasmacytoid features, lymph node, formalin fixation. Neoplastic B cells reveal strong membrane reactivity for CD138 (immunoperoxidase study, hematoxylin counterstain, ×400).
❚Image 5❚ Transitional carcinoma of bladder, formalin fixation. Strong membrane staining for CD138 is apparent. Stroma is nonreactive (immunoperoxidase study, hematoxylin counterstain, ×200).
❚Image 6❚ Medullary carcinoma of the thyroid, formalin fixation. Neoplastic cells exhibit immunoreactivity for CD138 characterized by a strong membrane staining pattern (immunoperoxidase study, hematoxylin counterstain, ×200).
gland myoepithelioma with marked plasmacytoid morphologic features showed diffuse, strong, membranous positivity. In the majority of reactive cases, most tumor cells were CD138+. Staining intensity showed variability within individual tumors but overall ranged from moderate to strong. Positivity was characterized by a membranous staining pattern in all except 2 cases, which exhibited additional weaker granular cytoplasmic staining. In 17 cases (breast, 7/9; gastric carcinoma, 1/5; small cell carcinoma, 2/2; non-small cell carcinoma, 5/5; colonic adenocarcinoma, 1/3; thymoma, 1/1), moderate to strong stromal staining was apparent. In 2 of these cases, the tumor cells were CD138-.
In the group of 21 nonepithelial neoplasms, CD138 reactivity was noted for 5 of 10 malignant melanomas, all of which exhibited epithelioid morphologic features and showed moderate to strong membranous positivity. Stromal positivity also was present in 6 of 10 cases. Two patterns of reactivity were observed in the 2 cases of synovial sarcoma. One case with biphasic morphologic features revealed strong membranous reactivity in the epithelial component and membranous and cytoplasmic reactivity in the spindle cell component. The other case, a monophasic spindle cell tumor, showed moderate membranous and cytoplasmic positivity. Of 2 leiomyosarcomas, 1 was CD138+. Only focal weak staining was observed in the 1 case of gastrointestinal stromal tumor examined, and no staining was seen in a schwannoma. Weak, focal membranous and cytoplasmic staining was seen in both cases of mesothelioma. Staining was absent in the 1 seminoma examined.
Other Observations
In nonneoplastic tissues, CD138 reactivity with a membranous staining pattern was noted for tonsillar squamous epithelium, stratified squamous and adnexal epithelium of the skin, prostate glandular epithelium, and thymic Hassall corpuscles. Sections of nerve, myometrium, and pancreas were negative. Sections of reactive lymph node, tonsil, spleen, and thymus also were evaluated in the microarray and revealed CD138 reactivity only for occasional plasma cells, tonsillar squamous epithelium, and Hassall corpuscles.
Immunoreactivity for CD138 was optimally preserved in Zenker-fixed bone marrow biopsy specimens, precluding the need for antigen retrieval before immunohistochemical studies. Although reactivity was preserved in B-5-fixed tissue, preliminary antigen retrieval provided enhanced staining. Antigen retrieval was required for optimal reactivity of formalin-fixed tissues. For all cases in which mouse IgG1 (isotype-specific) immunoglobulin was substituted for the primary antibody, no reactivity was observed.
Discussion
CD138/syndecan-1 is a cell membrane proteoglycan that functions as a matrix receptor and is expressed on the surface of mature epithelial cells 19, 20 and normal and neoplastic plasma cells. [8] [9] [10] CD138-clustered antibodies recognize syndecan-1 7, 8 and have been used in clinical practice in the evaluation and characterization of plasma cell dyscrasias.
❚Image 7❚ Metastatic squamous cell carcinoma of lung, soft tissue, formalin fixation. Tumor cells exhibit strong membrane reactivity for CD138 (immunoperoxidase study, hematoxylin counterstain, ×200).
❚Image 8❚ Adenocarcinoma, lung, formalin fixation. Strong membrane positivity for CD138 is observed for the neoplastic cells and for occasional plasma cells present in the stroma (immunoperoxidase study, hematoxylin counterstain, ×200).
The present study evaluated 238 specimens (298 specimens with inclusion of the microarray data) that included bone marrow biopsy specimens, lymph nodes, and a variety of other tissue specimens from patients with a broad spectrum of hematologic and nonhematologic neoplasms. Our findings support the findings in previously published reports demonstrating that CD138 is a highly specific and sensitive marker of plasmacytic differentiation within the spectrum of hematologic malignancy. 8, 9, 12 In the present study, CD138 expression in hematologic malignancy in bone marrow biopsy specimens was limited to nonneoplastic plasma cells, multiple myeloma, and lymphoplasmacytic lymphoma in which strong membrane staining of neoplastic plasma cells was a consistent finding. In the nodal and extranodal tissue samples in our study, the only NHLs exhibiting reactivity were 2 cases of immunoblastic DLBCL, both of which showed marked plasmacytoid morphologic features, and the plasmacytic component of marginal zone lymphomas. Interestingly, cases of DLBCL lacking plasmacytoid features were CD138-. These findings concur with those reported previously. 8, 9 Costes et al 8 observed CD138 reactivity for 5 of 13 large cell lymphomas with plasmacytoid morphologic features and for normal and neoplastic epithelia. In the study by Chilosi et al, 9 13 of 14 cases of immunoblastic DLBCL were CD138-; however, the presence or absence of plasmacytoid cytologic features was not reported. In our study, lesional cells in other hematopoietic diseases, including myeloproliferative disorders, precursor B-cell acute lymphoblastic leukemia, and a broad spectrum of lymphoid neoplasms, were CD138- (Tables 1  and 2 ). Our studies of nonneoplastic lymphoid tissue samples demonstrated that reactivity for CD138 was localized selectively to the plasma cell population, a finding also noted in other reports. 7, 8 Similar to the findings of previous bone marrow biopsy studies, [7] [8] [9] we found that CD138 staining was restricted to plasma cells. Other marrow elements, including stromal elements, mast cells, histiocytes, fat cells, osteoblasts and osteoclasts, and cells of hematopoietic lineage, typically are uniformly negative. However, in some neoplastic processes, stromal reactivity might be observed. Essentially all plasma cells were delineated distinctly on the basis of strong membranous CD138 immunoreactivity, providing a highly sensitive and specific marker for quantitation of plasma cells in bone marrow biopsy specimens.
For several years we have included CD138 studies for the assessment of bone marrow biopsy specimens of patients with plasma cell dyscrasias and have found this marker to be a valuable adjunct for precise quantitation of the plasma cell population. Some differences were apparent in comparing our findings with those in previous reports. One study 7 used the same clone (B-B4) of anti-CD138 antibody for analysis of bone marrow cells by flow cytometric or immunohistochemical analysis (Zenker-fixed tissue samples) and demonstrated some variability in consistency and/or uniformity of membrane reactivity. Stromal reactivity also was noted for most cases. In that study, antigen retrieval and a different detection system (LSAB2 [labeled streptavidin biotin] alkaline phosphatase, DAKO) were used. Because reactivity for CD138 is well preserved in Zenker-fixed tissue samples, as noted in our study, the use of antigen retrieval might have altered reactivity. Also, our study used a very sensitive conjugated polymer technique that might have contributed to the differences.
Costes et al 8 evaluated bone marrow biopsy specimens using a different monoclonal antibody (clone Mi15) and a different detection system, and excellent detection of plasma cells was noted. In the latter study, biopsy specimens were fixed in Bouin solution or in a formol-acetic acid-methanol solution. Chilosi et al 9 studied formalin-fixed bone marrow biopsy specimens by using antibody clone B-B4 and regarded CD138 as a sensitive and specific marker for plasma cells in bone marrow sections.
Overall, relatively similar results were obtained in all studies, suggesting that CD138 immunoreactivity is preserved using a variety of fixatives. It should be noted, however, that the Zenker-fixed marrow specimens in our study did not require antigen retrieval for optimal reactivity, a procedure that was used for tissues processed with the other fixatives. We have found Zenker fixation advantageous for bone marrow biopsy specimen processing because it provides superb cytologic detail and excellent preservation of immunoglobulin light and heavy chains in plasma cells, as well as CD138, features of particular value in assessing plasma cell proliferations.
A consensus does not exist regarding the presence of CD138 reactivity in B-cell chronic lymphocytic leukemia (B-CLL). Our findings are in agreement with the results of Costes et al 8 and Chilosi et al 9 but conflict with 2 other reports, 21, 22 which demonstrated CD138 in that disorder. We found all cases of B-CLL (14 bone marrow biopsy specimens and 5 lymph nodes) to be CD138-. In the studies by Sebestyen et al, 21, 22 syndecan-1 expression was demonstrated by flow cytometric and immunohistochemical analyses. In the latter studies, B-CLL cells revealed CD138 reactivity on the cell membrane and in the cytoplasm. A retrieval method (high temperature, pressure cooker; citrate solution) and a detection system different from those we used were used in those studies.
Our results for cases of Hodgkin lymphoma are discordant with previous reports that describe reactivity of RS cells in cases of classic Hodgkin lymphoma. 8, 11 CD138 reactivity was not observed for the neoplastic cell population in B-5-or formalin-fixed tissue samples in our 16 cases of classic Hodgkin lymphoma. However, plasma cells were reactive and, as previously described, 11 we observed strong CD138 reactivity within bands of stromal fibrosis. In the study by Costes et al, 8 RS cells and variants in 23 of 31 cases of classic Hodgkin lymphoma were positive, with fewer than 10% positive cells in 10 cases and 25% to 50% positive cells in 10 cases. A different CD138 antibody (clone Mi15) was used in that study, and similar results were noted for paraffin and cryostat sections. Paraffinembedded tissue samples in that study were fixed in Bouin fixative or formol-acetic acid-methanol solution; our study evaluated B-5-or formalin-fixed tissue samples. In the other study, 11 the B-B4 clone and a different sensitive detection system (alkaline phosphatase-anti-alkaline phosphatase technique) were used.
Technical considerations might be factors contributing to the discordance. In the previous reports, as in our cases, neoplastic cells in cases of nodular lymphocyte predominant Hodgkin lymphoma were negative. While the significance of the stromal reactivity in Hodgkin lymphoma is unclear, syndecan-1 might act as a coreceptor for basic fibroblast growth factor. This finding is reminiscent of the syndecan-1 up-regulation associated with fibroblast proliferation that has been demonstrated during wound healing 23, 24 and potentially might represent a contributory factor for the sclerosis in nodular sclerosis Hodgkin lymphoma.
Our study included samples from a broad range of nonhematologic tumors (epithelial and nonepithelial) to assess the spectrum of CD138 immunoreactivity and potential difficulties in differential diagnosis. A majority of epithelial neoplasms, both primary and metastatic, showed reactivity for CD138 for neoplastic cells and frequently also in stromal cells (Table 3 ; Images 3, 5-8). In comparison with the staining pattern of normal or neoplastic plasma cells and nonneoplastic mature epithelia, staining intensity for epithelial neoplasms was generally less uniform and background staining was greater. However, when present, membrane positivity of moderate to strong intensity was usual. No consistent difference in staining pattern between plasma cell neoplasms and epithelial tumors was detected. Therefore, CD138 as an isolated marker does not have any discriminatory role in the differential diagnosis of neoplasms with plasmacytoid features, unless a hematolymphoid derivation has been established. For evaluation of tumors of unknown origin, a panel that includes other appropriate markers must be used. This point is pertinent because several nonhematologic tumors can display conspicuous plasmacytoid morphologic features and might suggest a plasma cell origin on initial morphologic inspection, notably myoepithelioma, medullary carcinoma of the thyroid, and metastatic melanoma. CD138 reactivity was observed for each of these tumor types.
Assessment of reactivity for leukocyte common antigen (LCA) might be helpful for identifying potential CD138+ plasmacytic neoplasms because some of these tumors might exhibit LCA positivity for at least part of the cell population. 25 For neoplasms reactive for CD138 and LCA, additional studies for CD20 might help distinguish between a possible plasmacytic tumor (typically CD20-) and a DLBCL with plasmacytoid features (usually uniformly reactive for CD20). Accurate characterization of CD138+ nonhematopoietic tumors with plasmacytoid morphologic features should be achieved readily by including studies for cytokeratins, S-100 protein, and melanocytic markers in the immunohistochemical panel.
Stromal CD138 reactivity in the context of invasive breast carcinoma has been described previously 16 and was observed in most of our cases of breast carcinoma, including those in which the tumor cells were nonreactive for CD138 (Tables 1 and 3 , Image 3B). Furthermore, we found stromal positivity in a large subset of other cases of infiltrating carcinoma from a variety of different primary sites (Table 3) . No consistent correlation between intensity of stromal positivity and tumor cell positivity was demonstrated. Stromal staining for syndecan-1 reportedly is seen rarely outside the setting of developing tissues, wound healing, or both. 4, 5, 24 The functional significance of syndecan-1 expression in the setting of tumor stroma of epithelioid neoplasms remains to be elucidated; however, it has been postulated to have implications for tumor cell growth. 12, 16 Because CD138 interacts with heparin binding growth factors such as fibroblast growth factor-2, its accumulation in tumor stroma might contribute to angiogenesis, stromal proliferation, and tumor pathogenesis. Interestingly, syndecan-1/CD138 expression is not observed in the stroma of normal breast tissue or benign stromal-epithelial neoplasms. 16 In the present series, CD138 positivity also was seen in nonepithelial tumors, including melanoma, leiomyosarcoma, and synovial sarcoma. Synovial sarcomas showed a biphasic staining pattern similar to that reported by Orosz and Kopper, 17 with reactivity of both glandular and spindle cell elements. In the latter study of soft tissue neoplasms, cell membrane positivity was observed for epithelioid sarcomas and epithelial elements of synovial sarcomas, with intracytoplasmic positivity noted for gastrointestinal stromal tumors, some malignant epithelioid schwannomas, and some cases of fibromatosis. 18 Kaposi sarcoma, fibrosarcoma, dermatofibrosarcoma protuberans, and pyogenic granuloma were negative. Overall CD138 expression was regarded as heterogeneous and nonspecific as to tumor type. Although CD138 immunoreactivity does not represent a diagnostic discriminant to identify specific soft tissue tumors, membranous and/or cytoplasmic CD138 reactivity for some of these lesions represents part of their immunohistochemical staining profile. In our study, CD138-nonhematopoietic neoplasms included pheochromocytoma, seminoma, and schwannoma.
Our findings indicate that within the spectrum of hematologic disorders, CD138 expression is highly sensitive and specific for plasmacytic differentiation and represents an excellent marker for evaluation of plasma cell disorders in routinely processed tissue samples. CD138 is particularly helpful for plasma cell quantitation in bone marrow biopsy specimens. Reactivity for NHLs was restricted to the plasma cell component of lymphoplasmacytic lymphoma and marginal zone lymphoma and to DLBCL, immunoblastic with plasmacytoid features. Reactivity for CD138 also was observed in the majority of epithelial neoplasms and less consistently in a variety of nonepithelial neoplasms. Therefore, caution is required in the interpretation of CD138+ neoplasms for which a hematolymphoid derivation has not been established, particularly because some nonhematopoietic neoplasms might exhibit plasmacytoid features. A panel of appropriate marker studies should resolve these diagnostic problems. Although the broad profile of CD138 immunoreactivity essentially precludes its role as a diagnostic discriminant in nonhematologic disease, expression of syndecan-1/CD138 in these tumors might have a role in tumorigenesis by binding angiogenic or growth factors.
